Results 121 to 130 of about 177,018 (304)
Lymphoid‐Tissue‐on‐Chip Recapitulates Human Antibody Responses In Vitro
Advanced Science, EarlyView.The presented lymphoid‐tissue‐on‐chip system allows culture of primary human tonsil cells at organotypic high density under perfusion for up to 4 weeks, emulates immune response to soluble vaccines and vaccination via peripheral antigen‐presenting cells and represents a useful tool to assess cellular interactions during homeostasis, immune responses ...
Claudia Teufel +15 more
wiley +1 more source
Clinical & Translational ImmunologyObjectives To evaluate the manufacturability, efficacy and safety of allogeneic CD19 chimeric antigen receptor double‐negative T cells (CD19‐CAR‐DNTs) as an off‐the‐shelf therapeutic cell product.
Dan Wang +12 more
doaj +1 more source
Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion
Advanced Science, EarlyView.The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li +10 more
wiley +1 more source
Oncologic Emergencies: Immune-Based Cancer Therapies and Complications [PDF]
, 2020 Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from ...
Brém, Elizabeth +2 more
core
Advanced Science, EarlyView.This study reports the development of a fully humanized bispecific T cell engager targeting IL13RA2, a tumor‐associated antigen enriched in glioblastoma. This off‐the‐shelf immunotherapy drives potent, antigen‐dependent T cell activation and tumor killing, and prolongs survival in experimental GBM and other solid tumors models without detectable off ...
Joseph T. Duffy +16 more
wiley +1 more source
Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells [PDF]
, 2001 The inducible costimulator receptor (ICOS) is a third member of the CD28 receptor family that regulates T cell activation and function. ICOS binds to a newly identified ligand on antigen presenting cells different from the CD152 ligands CD80 and CD86. We
Aicher, A +9 more
core
Advanced Science, EarlyView.An mRNA‐liposome vaccine via dissolving microneedles (ML‐DMN) enables efficient skin‐targeted delivery while preserving mRNA integrity and allowing sustained antigen expression. Unlike intramuscular (IM) injection, ML‐DMN engages skin‐resident immune cells, activates antigen‐presenting cells (APCs), and induces strong T cell and cytokine responses at ...
Jeehye Nam +9 more
wiley +1 more source
Advanced Science, EarlyView.This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård +19 more
wiley +1 more source
Advanced Science, EarlyView.ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley +1 more source